Bioventus (NASDAQ:BVS) Updates FY 2026 Earnings Guidance

Key Points

• Bioventus updated FY2026 guidance: management expects EPS of $0.75–$0.79 (in line with the $0.75 consensus) and revenue of $600–$610 million versus the $604.7 million consensus.
• Analyst sentiment is positive: several recent upgrades left a consensus "Buy" rating and a $14.00 consensus price target after multiple firms raised ratings and targets.
• Stock trades below analyst target: NASDAQ:BVS opened at $10.68 with a market cap of about $888 million and a P/E of ~32.4, implying upside to the $14 consensus target.

Bioventus (NASDAQ:BVS - Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.7 million.

Analyst Upgrades and Downgrades

BVS has been the subject of several analyst reports. CJS Securities initiated coverage on shares of Bioventus in a research report on Friday, March 27th. They set a "market outperform" rating and a $14.00 price target for the company. Barrington Research boosted their price objective on shares of Bioventus from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, March 6th. Cantor Fitzgerald raised shares of Bioventus to a "strong-buy" rating in a research note on Wednesday, March 4th. Finally, Craig Hallum increased their target price on shares of Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $14.00.

Bioventus Stock Performance

NASDAQ:BVS opened at $10.68 on Wednesday. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The firm's fifty day simple moving average is $9.23 and its 200 day simple moving average is $8.16. The stock has a market cap of $888.04 million, a P/E ratio of 32.36 and a beta of 0.72. Bioventus has a twelve month low of $5.81 and a twelve month high of $10.76.

Bioventus (NASDAQ:BVS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts predict that Bioventus will post 0.76 EPS for the current year.

Insider Buying and Selling at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director owned 44,997 shares in the company, valued at approximately $395,523.63. This represents a 21.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 33.00% of the company's stock.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC lifted its position in Bioventus by 4.1% during the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company's stock valued at $44,993,000 after buying an additional 236,741 shares during the period. Vanguard Group Inc. grew its position in shares of Bioventus by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company's stock worth $19,567,000 after buying an additional 122,749 shares during the period. Geode Capital Management LLC grew its position in shares of Bioventus by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company's stock worth $8,337,000 after buying an additional 19,388 shares during the period. State Street Corp increased its stake in shares of Bioventus by 1.7% in the 4th quarter. State Street Corp now owns 891,024 shares of the company's stock worth $6,629,000 after acquiring an additional 14,590 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Bioventus by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 765,208 shares of the company's stock valued at $5,693,000 after acquiring an additional 21,777 shares during the period. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.